Overview

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The FSGS Clinical Trial is a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 months.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator:
The Cleveland Clinic
Treatments:
BB 1101
Cyclosporine
Cyclosporins
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate